Compare Equinix Inc (EQIX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs TG Therapeutics Inc — how do they compare? Equinix Inc trades at $1,026.06 (market cap $99.77B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Equinix Inc is far larger — about 12.2× TG Therapeutics Inc's market cap, and Equinix Inc pays a 2.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and TG Therapeutics Inc for 16 Days on average.
| EQIX | TGTX | |
|---|---|---|
Market Cap | $99.77B | $8.16B |
Volume | 480,425 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $59.06 |
52-Week Low | $726.09 | $26.94 |
Typical Hold Time | 110 Days | 16 Days |
Enterprise Value | $120.90B | $8.37B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,011.16, down 2.0% on the day amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $9.22B in 2025 and a net income margin of 15.63%, though valuation ratios like a P/E of 65.07 appear elevated. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 and Q4 2025 missing. Analyst sentiment remains bullish with a $1,250 consensus price target, supported by strong AI-driven data center demand highlighted in recent news.
The outlook for EQIX is positive due to robust AI infrastructure demand and a solid dividend, but risks include high capital expenditures and debt levels. Investors should weigh growth potential against valuation concerns and execution risks in a competitive sector.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
